Oxidative phosphorylation dysfunction modulates expression of extracellular matrix - Remodeling genes and invasion

Carcinogenesis

Volumn 27, Issue 3, 2006, Pages 409-418

  van Waveren, Corina ^a   Sun, Yubo ^a   Cheung, Herman S ^a   Moraes, Carlos T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; MATRIGEL; MATRIX METALLOPROTEINASE; MITOCHONDRIAL DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UROKINASE;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL POPULATION; CONTROLLED STUDY; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; TRANSCRIPTION REGULATION; WILD TYPE;

BONE NEOPLASMS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; MITOCHONDRIA; NEOPLASM INVASIVENESS; OSTEOSARCOMA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PLASMINOGEN INACTIVATORS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 33644870379     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi242     Document Type: Article

References (57)

1. Kalckar,H.M. (1991) 50 years of biological research - from oxidative phosphorylation to energy requiring transport regulation. Annu. Rev. Biochem., 60, 1-37.
2. Gause,G.F. (1969) Cancer and mitochondrial DNA. Br. Med. J., 3, 413-414.
3. Jiang,X. and Wang,X. (2004) Cytochrome c-mediated apoptosis. Annu. Rev. Biochem., 73, 87-106.
4. Liu,V.W., Shi,H.H., Cheung,A.N., Chiu,P.M., Leung,T.W., Nagley,P., Wong,L.C. and Ngan,H.Y. (2001) High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res., 61, 5998-6001.
5. Holme,E., Larsson,N.G., Oldfors,A., Tulinius,M., Sahlin,P. and Stenman,G. (1993) Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A→G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and raggedred fibers (MERRF) syndrome. Am. J. Hum. Genet., 52, 551-556.
6. Silvestri,G., Ciafaloni,E., Santorelli,F.M., Shanske,S., Servidei,S., Graf,W.D., Sumi,M. and DiMauro,S. (1993) Clinical features associated with the A→G transition at nucleotide 8344 of mtDNA ("MERRF mutation). Neurology, 43, 1200-1206.
7. Taylor,R.W. and Turnbull,D.M. (2005) Mitochondrial DNA mutations in human disease. Nat. Rev. Genet., 6, 389-402.
8. + signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: A novel mode of inter-organelle crosstalk. EMBO J., 18, 522-533.
9. Biswas,G., Anandatheerthavarada,H.K., Zaidi,M. and Avadhani,N.G. (2003) Mitochondria to nucleus stress signaling: A distinctive mechanism of NFkappaB/Rel activation through calcineurin-mediated inactivation of IkappaBbeta. J. Cell Biol., 161, 507-519.
10. Amuthan,G., Biswas,G., Zhang,S.Y., Klein-Szanto,A., Vijayasarathy,C. and Avadhani,N.G. (2001) Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J., 20, 1910-1920.
11. Amuthan,G., Biswas,G., Ananadatheerthavarada,H.K., Vijayasarathy,C., Shephard,H.M. and Avadhani,N.G. (2002) Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene, 21, 7839-7849.
12. Wada,Y., Kato,S., Okamoto,K., Izumaru,S., Aoyagi,S. and Morimatsu,M. (2001) Diltiazem, a calcium antagonist, inhibits matrix metalloproteinase-1 (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells. Int. J. Mol. Med., 8, 561-566.
13. Winberg,J.O., Berg,E., Kolset,S.O. and Uhlin-Hansen,L. (2003) Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur. J. Biochem., 270, 3996-4007.
14. Munshi,H.G., Wu,Y.I., Ariztia,E.V. and Stack,M.S. (2002) Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J. Biol. Chem., 277, 41480-41488.
15. Popp,O., Heidinger,M., Ruiz-Heinrich,L., Ries,C., Jochum,M. and Gil-Parrado,S. (2003) The calpastatin-derived calpain inhibitor CP1B reduces mRNA expression of matrix metalloproteinase-2 and -9 and invasion by leukemic THP-1 cells. Biol. Chem., 384, 951-958.
16. Barrientos,A. and Moraes,C.T. (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. J. Biol. Chem., 274, 16188-16197.
17. Palacios-Callender,M., Quintero,M., Hollis,V.S., Springett,R.J. and Moncada,S. (2004) Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc. Natl Acad. Sci. USA, 101, 7630-7635.
18. King,M.P. (1996) Use of ethidium bromide to manipulate ratio of mutated and wild-type mitochondrial DNA in cultured cells. Methods Enzymol., 264, 339-344.
19. Moraes,C.T., Dey,R. and Barrientos,A. (2001) Transmitochondrial technology in animal cells. Methods Cell Biol., 65, 397-412.
20. Diaz,F., Bayona-Bafaluy,M.P., Rana,M., Mora,M., Hao,H. and Moraes,C.T. (2002) Human mitochondrial DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy number control. Nucleic Acids Res., 30, 4626-4633.
21. Moraes,C.T., Shanske,S., Tritschler,H.J., Aprille,J.R., Andreetta,F., Bonilla,E., Schon,E.A. and DiMauro,S. (1991) mtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases. Am. J. Hum. Genet., 48, 492-501.
22. Yang,Y.H., Dudoit,S., Luu,P., Lin,D.M., Peng,V., Ngai,J. and Speed,T.P. (2002) Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res., 30, e15.
23. Benjamini,Y. and Hochberg,Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. Roy. Stat. Soc. Series B, 57, 289-230.
24. Draghici,S., Khatri,P., Martins,R.P., Ostermeier,G.C. and Krawetz,S.A. (2003) Global functional profiling of gene expression. Genomics, 81, 98-104.
25. Khatri,P., Draghici,S., Ostermeier,G.C. and Krawetz,S.A. (2002) Profiling gene expression using onto-express. Genomics, 79, 266-270.
26. Lekanne Deprez,R.H., Fijnvandraat,A.C., Ruijter,J.M. and Moorman,A.F. (2002) Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem., 307, 63-69.
27. Marino,J.H., Cook,P. and Miller,K.S. (2003) Accurate and statistically verified quantification of relative mRNA abundances using SYBR Green I and real-time RT-PCR. J. Immunol. Methods, 283, 291-306.
28. Sun,Y., Zeng,X.R., Wenger,L., Firestein,G.S. and Cheung,H.S. (2004) P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J. Cell Biochem., 92, 258-69.
29. Bai,G., Howell,D.S., Howard,G.A., Roos,B.A. and Cheung,H.S. (2001) Basic calcium phosphate crystals up-regulate metalloproteinases but down-regulate tissue inhibitor of metalloproteinase-1 and -2 in human fibroblasts. Osteoarthritis Cartilage, 9, 416-422.
30. Zempo,N., Koyama,N., Kenagy,R.D., Lea,H.J. and Clowes,A.W. (1996) Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb. Vasc. Biol., 16, 28-33.
31. Dallas,S.L., Sivakumar,P., Jones,C.J., Chen,Q., Peters,D.M., Mosher,D.F., Humphries,M.J. and Kielty,C.M. (2005) Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J. Biol. Chem., 280, 18871-18880.
32. Kermorgant,S., Aparicio,T., Dessirier,V., Lewin,M.J. and Lehy,T. (2001) Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis, 22, 1035-1042.
33. Brini,M., Pinton,P., King,M.P., Davidson,M., Schon,E.A. and Rizzuto,R. (1999) A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat. Med., 5, 951-954.
34. Harbeck,N. and Thomssen,C. (2003) [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]. Zentralbl Gynakol., 125, 362-367.
35. Planque,N. and Perbal,B. (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int., 3, 15.
36. Clark,K.M., Brown,T.A., Davidson,M.M., Papadopoulou,L.C. and Clayton,D.A. (2002) Differences in nuclear gene expression between cells containing monomer and dimer mitochondrial genomes. Gene, 286, 91-104.
37. Park,S.Y., Choi,B., Cheon,H., Pak,Y.K., Kulawiec,M., Singh,K.K. and Lee,M.S. (2004) Cellular aging of mitochondrial DNA-depleted cells. Biochem. Biophys. Res. Commun., 325, 1399-1405.
38. Miceli,M.V. and Jazwinski,S.M. (2005) Common and cell type-specific responses of human cells to mitochondrial dysfunction. Exp. Cell. Res., 302, 270-280.
39. Denko,N.C., Fontana,L.A., Hudson,K.M., Sutphin,P.D., Raychaudhuri,S., Altman,R. and Giaccia,A.J. (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 22, 5907-5914.
40. Michelson,S. and Leith,J.T. (1996) Host response in tumor growth and progression. Invasion Metastasis, 16, 235-246.
41. Leo,C., Giaccia,A.J. and Denko,N.C. (2004) The hypoxic tumor microenvironment and gene expression. Semin. Radiat. Oncol., 14, 207-214.
42. Bardos,J.I. and Ashcroft,M. (2004) Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays, 26, 262-9.
43. Simonnet,H., Demont,J., Pfeiffer,K., Guenaneche,L., Bouvier,R., Brandt,U., Schagger,H. and Godinot,C. (2003) Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis, 24, 1461-1466.
44. Simonnet,H., Alazard,N., Pfeiffer,K., Gallou,C., Beroud,C., Demont,J., Bouvier,R., Schagger,H. and Godinot,C. (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis, 23, 759-768.
45. Petros,J.A., Baumann,A.K., Ruiz-Pesini,E. et al. (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA, 102, 719-724.
46. Shidara,Y., Yamagata,K., Kanamori,T., Nakano,K., Kwong,J.Q., Manfredi,G., Oda,H. and Ohta,S. (2005) Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res., 65, 1655-1663.
47. Sliva,D. (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr. Cancer Drug Targets, 4, 327-336.
48. Higuchi,M., Manna,S.K., Sasaki,R. and Aggarwal,B.B. (2002) Regulation of the activation of nuclear factor kappaB by mitochondrial respiratory function: Evidence for the reactive oxygen species-dependent and -independent pathways. Antioxid. Redox Signal, 4, 945-955.
49. Wenk,J., Brenneisen,P., Wlaschek,M., Poswig,A., Briviba,K., Oberley,T.D. and Scharffetter-Kochanek,K. (1999) Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloprotease-1. J. Biol. Chem., 274, 25869-25876.
50. Sliva,D., Rizzo,M.T. and English,D. (2002) Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J. Biol. Chem., 277, 3150-3157.
51. Vulin,A.I. and Stanley,F.M. (2004) Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J. Biol. Chem., 279, 25172-25178.
52. Sato,T., Koike,L., Miyata,Y., Hirata,M., Mimaki,Y., Sashida,Y., Yano,M. and Ito,A. (2002) Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res., 62, 1025-1029.
53. Andela,V.B., Gordon,A.H., Zotalis,G., Rosier,R.N., Goater,J.J., Lewis,G.D., Schwarz,E.M., Puzas,J.E. and O'Keefe,R.J. (2003) NFkappaB: A pivotal transcription factor in prostate cancer metastasis to bone. Clin. Orthop., S75-S85.
54. Trim,J.E., Samra,S.K., Arthur,M.J., Wright,M.C., McAulay,M., Beri,R. and Mann,D.A. (2000) Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein. J. Biol. Chem., 275, 6657-6663.
55. Kunz,M., Moeller,S., Koczan,D., Lorenz,P., Wenger,R.H., Glocker,M.O., Thiesen,H.J., Gross,G. and Ibrahim,S.M. (2003) Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J. Biol. Chem., 278, 45651-45660.
56. Zhao,Y., Xue,Y., Oberley,T.D., Kiningham,K.K., Lin,S.M., Yen,H.C., Majima,H., Hines,J. and St Clair,D. (2001) Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. Cancer Res., 61, 6082-6088.
57. Hervouet, E., Demont, J., Pecina, P., Vojtiskova, A., Houstek, J., Simonnet, H. and Godinot, C. (2005) A new role for the von Hippel-Lindau tumor suppresser protein: Stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis, 26, 531-539.